Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Borderline Personality DisorderMajor Depressive Disorder

Interventions

DRUG

Psilocybin

Psilocybin 25mg capsule

Trial Locations (1)

University of Chicago, Chicago

All Listed Sponsors

collaborator

Usona Institute

OTHER

lead

University of Chicago

OTHER

NCT05399498 - Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder | Biotech Hunter | Biotech Hunter